Stockscreener 앱 받기
2.20
1.38%
0.03
시장 영업 전:
2.20
전일 마감가:
$2.17
열려 있는:
$2.2
하루 거래량:
9,924
Relative Volume:
0.34
시가총액:
$15.44M
수익:
$1.34M
순이익/손실:
$-13.49M
주가수익비율:
-0.1773
EPS:
-12.4093
순현금흐름:
$-3.07M
1주 성능:
+4.27%
1개월 성능:
+16.40%
6개월 성능:
-45.95%
1년 성능:
+0.00%
1일 변동 폭
$2.18
$2.34
1주일 범위
$2.11
$2.37
52주 변동 폭
$1.75
$12.87
Vyome Holdings Inc Stock (HIND) Company Profile
명칭
Vyome Holdings Inc
전화
949-429-6680
주소
1001 CALLE AMANECER, SAN CLEMENTE
Compare HIND vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
HIND
Vyome Holdings Inc
|
2.20 | 15.23M | 1.34M | -13.49M | -3.07M | -12.41 |
VRTX
Vertex Pharmaceuticals Inc
|
453.17 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.73 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
878.49 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
281.90 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
156.58 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Vyome Holdings Inc 주식(HIND)의 최신 뉴스
ReShape Lifesciences Stock Rocketed 37% Today – Here’s Why - MSN
HIND Q1 2026 Earnings: EPS Surprises Positive as Cost Control Takes Center StageAnalyst Earnings Estimate - newsline.com
HIND Q1 2026 Earnings: EPS Surprises with 18.3% Beat Amid Revenue UncertaintyFiscal Year Earnings - newsline.com
HIND Q1 2026 Earnings: EPS Beats Estimates as Losses Narrow; Stock RisesCFO Commentary Report - newsline.com
Vyome to present VT-1953 Phase 2 data at cancer research meeting - Investing.com
Earnings call transcript: Vyome Holdings Q1 2026 shows strong cash position - Investing.com
HIND Q1 2026 Earnings: EPS Beats Estimates as Development Pipeline AdvancesSurprise Factor Analysis - The Legal Advocate
HIND Q1 2026 Earnings: EPS Surpasses Estimates as Company Advances PipelineROA Comparison - The Legal Advocate
Vyome Holdings reports Q1 2026: $8.8M cash, $10.2M total assets, net loss $986K - TradingView
Press Release: Vyome Holdings Reports First Quarter 2026 Results With Key FDA Filings and Strong Balance Sheet - Moomoo
Vyome Holdings Reports First Quarter 2026 Results With Key FDA Filings and Strong Balance Sheet - BioSpace
Vyome Holdings (HIND.US) will release its earnings report on June 3. - Moomoo
HIND Q1 2026 Earnings: EPS Beats Estimates Despite Revenue AbsenceDownward Estimate Revision - The Legal Advocate
HIND Q1 2026 Earnings: EPS Beat Despite Limited Revenue VisibilityEPS Consistency Score - The Legal Advocate
Vyome Holdings Inc. (HIND) Q4 2025 Earnings: Significant EPS Beat Highlights Cost DisciplineProfessional Trade Ideas - Newser
HIND News | VYOME HOLDINGS INC (NASDAQ:HIND) - ChartMill
Vyome Holdings (HIND) Stock Analysis: -1.56% Loss — Key Levels 2026-05-15Retail Trader Ideas - Newser
Vyome Holdings inks agreement with Impetis Biosciences to in-license two selective JAK inhibitor assets - BioSpectrum India
Vyome secures exclusive license from Impetis for selective JAK inhibitor programs - Indian Pharma Post
Vyome Holdings, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Vyome strikes deal with Impetis Biosciences, opening a ~$57B market opportunity - marketscreener.com
Vyome Strikes Deal With Impetis Biosciences, Opening A ~$57B Market Opportunity - The Joplin Globe
How Vyome Holdings (HIND) compares to the market average (Weakens) 2026-05-08Dealer Positioning - The Legal Advocate
HIND Stock Price, Quote & Chart | VYOME HOLDINGS INC (NASDAQ:HIND) - ChartMill
HIND (Vyome Holdings) shares fall 2.86% despite Q4 2025 EPS beating analyst estimates by a wide 40% margin.Stock Market Community - newser.com
The next big opportunity lies in immune and rare disease white spaces: Venkat Nelabhotla, President & CEO, Vyome Holdings - Indian Pharma Post
The next big opportunity lies in immune and rare disease white spaces: Venkat Nelabhotla, President & CEO, Vyome Holdings, Inc. - Indian Pharma Post
What could go wrong with Vyome Holdings (HIND) stock | Q4 2025: Earnings Beat EstimatesBeat Estimates - newser.com
Vyome Presents Transformational VT-1953 Phase 2 Clinical Study Data at Prestigious AACR 2026 - BioSpace
Maxim Group Maintains Vyome Holdings(HIND.US) With Buy Rating, Maintains Target Price $15 - Moomoo
Vyome reports positive phase 2 results for cancer wound treatment By Investing.com - Investing.com Australia
Vyome reports positive phase 2 results for cancer wound treatment - Investing.com
HIND Financials: Income Statement, Balance Sheet & Cash Flow | Vyome Holdings, Inc. - Stock Titan
Vyome Holdings (HIND) Stock Consolidates (Eye on Rally) 2026-04-20Social Trading Insights - Xã Châu Thành
Vyome Holdings (HIND) Stock: Why Institutions Watch It (Ticks Lower) 2026-04-18Shared Trade Ideas - Xã Thanh Hà
Vyome Holdings (HIND) Stock Historical Volatility (Ticks Lower) 2026-04-18Stock Surge Alerts - The Legal Advocate
Vyome Holdings (STU:24O0) PB Ratio : 0.00 (As of Apr. 16, 2026) - GuruFocus
Vyome Holdings, Inc. (HIND) stock price, news, quote and history - Yahoo Finance UK
Breaking News about Vyome Holdings, Inc.Common Stock (Nasdaq:HIND) - FinancialContent
Vyome to Present Compelling Phase 2 Clinical Data on VT-1953 for Treatment of MFW at AACR 2026 - BioSpace
Vyome to present VT-1953 Phase 2 data at cancer research meeting By Investing.com - Investing.com South Africa
HIND Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Vyome Holdings bolsters financial position to support VT-1953 pivotal study through 2027 - Indian Pharma Post
RSLS Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Vyome Holdings Inc (HIND) Q4 2025 Earnings Call Highlights: Strategic Advances Amid Financial ... By GuruFocus - Investing.com Canada
HIND Technical Analysis & Stock Price Forecast - Intellectia AI
HIND Should I Buy - Intellectia AI
Vyome Holdings Inc (HIND) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.27%
1.43%
자본화:
|
볼륨(24시간):